Melancholic Features and Lamotrigine Response in Bipolar II Depression
About this title
Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine
Read the official source — NCT02989727Researchers compared Lamotrigine and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Understand this study
What did researchers investigate?
Researchers compared Lamotrigine and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- SaskatoonSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 150
- Sponsor
- University of Saskatchewan
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- Over 18 Years
- Official registry ID
- NCT02989727
- Official title
Show the full official title
Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine: Results From an 8-week, Multicenter, Double-blind, Placebo-controlled Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Saskatoon
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Lamotrigine and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Who is behind this study?
The study sponsor is University of Saskatchewan, a university.
Did this study involve medication?
Yes. The study involved medication, including lamotrigine and Placebos.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
